• Monthly News Roundup - December 2023

    Landmark FDA Approval for Casgevy, a CRISPR-Based Therapy for Sickle Cell Disease 
    This past month the U.S. Food and Drug Administration (FDA) cleared Casgevy (exagamglogene autotemcel), the first approved CRISPR/Cas9 genome-edited cell...

Follow @Pharma_NewsUS on Twitter!